[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Higurashi M, Yagishita S, Fujitsu K, Kitsuta Y, Takemoto Y, Osano S: Plasma cell myeloma of the skull base: report of two cases. Brain Tumor Pathol; 2004;21(3):135-41
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma of the skull base: report of two cases.
  • Plasma cell myeloma (PCM) of the skull base is rarely encountered in neurosurgical practice.
  • PCM has a wide spectrum of pathology, including a quite benign, solitary plasmacytoma (SPC), and an extremely malignant, multiple myeloma (MM) at the two ends of the spectrum.
  • In case 1, a 46-year-old man presented with left multiple cranial nerve impairments and had a large skull base tumor.
  • The specimen revealed a plasmablastic tumor, i.e., myeloma.
  • She was administrated adjuvant chemotherapy and autologous bone marrow transplantation.
  • [MeSH-major] Multiple Myeloma / pathology. Plasmacytoma / pathology. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696975.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Browne M, Abramson LP, Chou PM, Acton R, Holinger LD, Reynolds M: Inflammatory myofibroblastic tumor (inflammatory pseudotumor) of the neck infiltrating the trachea. J Pediatr Surg; 2004 Oct;39(10):e1-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor (inflammatory pseudotumor) of the neck infiltrating the trachea.
  • Inflammatory myofibroblastic tumor (IMT), popularly known as inflammatory pseudotumor, is a slow growing quasi-neoplastic lesion with a distinct histologic appearance and benign clinical course.
  • A review of the pertinent literature and the etiology, diagnosis, treatment, and outcomes of this tumor are discussed.
  • A surgeon must not perform radical surgery, radiation, or chemotherapy until a final pathologic diagnosis is made because of the nature of this lesion.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Neoplasms, Second Primary / surgery. Tracheal Neoplasms / surgery
  • [MeSH-minor] Asthma / etiology. Bronchoscopy. Child. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486877.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Laurent S, Mouthon L, Longchampt E, Roudaire M, Franc S, Krivitzky A, Cohen R: Medical cure of plasma cell granuloma of the thyroid associated with Hashimoto's thyroiditis: a case report and review. J Clin Endocrinol Metab; 2004 Apr;89(4):1534-7
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical cure of plasma cell granuloma of the thyroid associated with Hashimoto's thyroiditis: a case report and review.
  • Plasma cell granuloma (PCG) is a rare, benign inflammatory tumor composed of myofibroblasts, abundant plasma cells, and lymphocytes combined with collagen.
  • A thyroid localization of PCG is extremely rare, and surgical therapy is indicated.
  • We report the case of a 35-yr-old woman with a thyroid PCG, associated with Hashimoto's thyroiditis, that was responsible for tracheal compression.
  • The patient was treated with corticosteroids and immunosuppressive therapy.
  • We also review other reports of thyroid PCG in the literature and discuss the differential diagnosis and treatment.
  • Although the use of immunosuppressive therapy has never been reported for thyroid PCG until now, this treatment may represent a good alternative to surgery in life-threatening, unresectable PCG.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Granuloma, Plasma Cell / drug therapy. Granuloma, Plasma Cell / etiology. Immunosuppressive Agents / therapeutic use. Thyroid Diseases / drug therapy. Thyroid Diseases / etiology. Thyroiditis, Autoimmune / complications

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15070909.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents
  • [Number-of-references] 20
  •  go-up   go-down


Advertisement
4. Matsuzaki H, Kobayashi H, Yagyu T, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T: Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol; 2005 Mar 1;23(7):1463-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma bikunin as a favorable prognostic factor in ovarian cancer.
  • PURPOSE: Bikunin is a multifunctional glycoprotein, which mediates suppression of tumor cell invasion and metastasis.
  • The measurement of bikunin levels in the tissue of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the evaluation of prognosis.
  • The high bikunin expression in ovarian cancer tissue would enable the use of soluble bikunin protein present in the circulation of ovarian cancer patients as a biomarker of disease.
  • PATIENTS AND METHODS: We developed a double-antibody immunoassay for bikunin and detected its presence in normal human circulation.
  • We quantified, by enzyme-linked immunosorbent assay and/or immunoblot assay bikunin in sera from 200 healthy women (controls), 200 patients with benign gynecologic diseases, and 327 patients with ovarian cancer before surgical removal of the tumor.
  • RESULTS: When the values of bikunin corresponding to the median were used as the cutoff value (11.5 microg/mL), low plasma bikunin was strongly associated with late-stage, suboptimal debulking with large residual tumor (> 2 cm) and low response to chemotherapy.
  • The median survival time of the patients with a high bikunin level was more than 60 months as compared with 26 months among those with low bikunin level (P = .002).
  • This difference corresponded to a 2.2-fold increased risk of dying for the lower plasma bikunin patients (hazard ratio, 0.45; P = .023) and remained significant in multivariate analysis (hazard ratio, 0.63; P = .041).
  • CONCLUSION: Preoperative plasma bikunin concentration is a strong and independent favorable prognostic marker for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Ovarian Neoplasms / mortality. Trypsin Inhibitor, Kunitz Soybean / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735122.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / SPINT2 protein, human; 9088-41-9 / Trypsin Inhibitor, Kunitz Soybean
  •  go-up   go-down


5. Moxnes JF, Haux J, Hausken K: The dynamics of cell proliferation. Med Hypotheses; 2004;62(4):556-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dynamics of cell proliferation.
  • A model is developed which enables us to describe and predict the dynamics of cell proliferation much better than by using ordinary curve fitting procedures.
  • By using differential equations the ability to foresee the dynamics of cell proliferation is in general much better than by using polynomial extrapolations.
  • Complex time relations can be revealed.
  • The mass of each living cell and the number of living cells are described as functions of time, accounting for each living cell's age since cell-birth.
  • The linkage between micro-dynamics and the population dynamics is furnished by coupling the mass increase of each living cell up against the mitosis rate.
  • A comparison is made by in vitro experiments with cancer cells exposed to digitoxin, a new promising anti-cancer drug.
  • Theoretical results for the total number of cells (living or dead) is found to be in good agreement with experiments for the cell line considered, assuming different concentrations of digitoxin.
  • It is shown that for the chosen cell line, the proliferation is halted by an increased time from birth to mitosis of the cells.
  • The delay is probably connected with changes in the Ca concentration inside the cell.
  • The enhanced time between the birth and mitosis of a cell leads effectively to smaller mitosis rates and thereby smaller proliferation rates.
  • This mechanism is different from the earlier results on digitoxin for different cell lines where an increased rate of apoptosis was reported.
  • But we find it reasonable that cell lines can react differently to digitoxin.
  • A development from enhanced time between birth and mitosis to apoptosis can be furnished, dependent of the sensitivity of the cell lines.
  • This mechanism is in general very different from the mechanism appealed to by standard chemotherapy and radiotherapy where the death ratios of the cells are mainly affected.
  • This is important, since by appealing to different types of mechanism in parallel during cancer treatment, more selectivity in the targeting of benign versus malignant cells can be invoked.
  • This increases the probability of successful treatment.
  • The critical digitoxin level concentration, i.e. the concentration level where the number of living cells is not increasing, is approximately 50 ng/ml for the cell line we investigated in this article.
  • Therapeutic plasma concentration of digitoxin when treating cardiac congestion is about 15-33 ng/ml, but individual tolerances are large.
  • The effect of digitoxin during cancer treatment is therefore very promising.
  • The dynamic model constitutes a new powerful tool, supported by empirics, describing the mechanism or process by which the number of malignant cells during anti-cancer treatment can be studied and reduced.
  • [MeSH-major] Cell Division / physiology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Calcium / metabolism. Cell Count. Cell Line, Tumor. Computer Simulation. Digitoxin / pharmacology. Dose-Response Relationship, Drug. Humans. Mathematics. Mitosis / drug effects. Models, Biological. Models, Theoretical. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DIGITOXIN .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050107.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E90NZP2L9U / Digitoxin; SY7Q814VUP / Calcium
  •  go-up   go-down


6. De Milito A, Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol; 2005 Dec;1(6):779-86
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor acidity, chemoresistance and proton pump inhibitors.
  • Tumor microenvironment may play a key role in tumor malignancy.
  • It is hypothesized that hypoxia and acidity may contribute to the progression from benign to malignant growth.
  • In particular, the unfavorable environment may induce the selection of tumor cells able to survive in acidic and hypoxic conditions.
  • In fact, the common components of the cancer phenotype result from active selection, and characteristics of tumor microenvironment may create the best condition for this selection.
  • Acidity, in particular, has been shown to have a role in resistance to chemotherapy, proliferation and metastatic behavior.
  • In fact, a mechanism of resistance to cytotoxic drugs may be the alteration of the tumor microenvironment through changes of the pH gradient between the extracellular environment and cell cytoplasm.
  • The extracellular pH of solid tumors is significantly more acidic than that of normal tissues, thus impairing the uptake of weakly basic chemotherapeutic drugs and reducing their effect on tumors.
  • An important determinant of tumor acidity is the anaerobic metabolism that allows selection of cells able to survive in an hypoxic-anoxic environment with the generation of lactate.
  • Malignant tumor cells seem to hijack some of these mechanism to protect themselves from the acidic environment and to maintain acidity in an environment unsuitable for normal or more differentiated cells.
  • Recent data suggest that vacuolar-type (V-type) H(+)-ATPases, that pump protons across the plasma membrane, may have a key role in the acidification of the tumor microenvironment.
  • Some human tumor cells are characterized by an increased V-type H(+)-ATPase expression and activity, and pretreatment with proton pump inhibitors -- a class of H(+)-ATPase inhibitors -- sensitized tumor cell lines to the effect of a variety of anticancer drugs.
  • Proton pump inhibitor pretreatment has been associated with inhibition of V-type H(+)-ATPase activity and increase in both extracellular pH and pH of lysosomal organelles.
  • In vivo experiments in human/mouse xenografts have shown that oral pretreatment with proton pump inhibitors is able to sensitize human solid tumors to anticancer drugs.
  • These data suggest that tumor alkalinization may represent a key target of future antitumor strategies.
  • [MeSH-major] Acid-Base Equilibrium. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Proton Pump Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556057.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proton Pump Inhibitors
  • [Number-of-references] 71
  •  go-up   go-down


7. Kuroi K, Tanaka C, Toi M: Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol; 2001 Jul;19(1):143-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of plasma nucleosome levels in cancer patients.
  • The nucleosome is the primary repeating unit of DNA organization in chromatin, and cell death may lead to increased levels of circulating nucleosomes in plasma (PNLs) in various circumstances such as inflammation, pulmonary embolism, autoimmune disease, and cancer.
  • Cell death can also be induced by chemotherapeutic agents.
  • We investigated PNLs in 99 patients with primary breast cancer, 26 with recurrent disease, 11 with benign breast disease, and 27 with other histological types of cancer.
  • In 18 patients with recurrent breast cancer who received docetaxel (D, 60 mg/m2) every 3 weeks as second line therapy after an anthracycline-based regimen, PNLs were investigated before and during the administration of D.
  • PNLs were detected using the cell death detection ELISAplus kit.
  • Patients with other histological types of cancer (0.244+/-0.383) also showed significantly higher PNLs as compared to healthy controls (p < 0.01), and PNLs were elevated independently of the histological type of cancer.
  • Thus, increased PNLs were found in cancer patients, and PNLs seem to be a sensitive marker of cell death that could be predictive of both leukopenia and response to chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Neoplasms / blood. Nucleosomes / metabolism. Taxoids
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / therapeutic use. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukocyte Count. Male. Mastectomy. Middle Aged. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408935.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Nucleosomes; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Karnak I, Senocak ME, Ciftci AO, Cağlar M, Bingöl-Koloğlu M, Tanyel FC, Büyükpamukçu N: Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg; 2001 Jun;36(6):908-12
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: diagnosis and treatment.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm.
  • Herein, the authors present their experience with IMT with special emphasis on diagnosis and treatment.
  • Tumor sizes ranged from 3 x 2 x 2 cm to 15 x 15 x 13 cm.
  • Total surgical excision of IMT was considered adequate for treatment in 6 cases.
  • One patient with aggressive IMT required further treatments such as immunomodulation and chemotherapy and died of neutropenic sepsis.
  • CONCLUSIONS: IMT is a benign neoplasm rarely presented with malignant features such as local invasiveness, recurrence, distant metastasis, or malignant transformation.
  • Complete surgical resection and close follow-up are all necessary for appropriate treatment to avoid recurrences as well as unnecessary and potentially harmful therapy.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery
  • [MeSH-minor] Child. Female. Humans. Male. Recurrence. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11381424.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


9. Gallazzi F, Wang Y, Jia F, Shenoy N, Landon LA, Hannink M, Lever SZ, Lewis MR: Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjug Chem; 2003 Nov-Dec;14(6):1083-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene.
  • The B-cell lymphoma/leukemia-2 (bcl-2) proto-oncogene has been associated with the transformation of benign lesions to malignancy, disease progression, poor prognosis, reduced survival, and development of resistance to radiation and chemotherapy in many types of cancer.
  • The objective of this work was to synthesize an antisense peptide nucleic acid (PNA) complementary to the first six codons of the bcl-2 open reading frame, conjugated to a membrane-permeating peptide for intracellular delivery, and modified with a bifunctional chelating agent for targeting imaging and therapeutic radiometals to tumors overexpressing bcl-2.
  • Synthesis of the DOTA-PNA conjugates was followed by automated elongation with a peptide sequence (PTD-4-glycine, PTD-4-G), known to mediate cellular internalization of impermeable effector molecules, or its retro-inverso analogue (ri-PTD-4-G).
  • Plasma stability studies showed that (111)In-DOTA-labeled ri-PTD-4-G-anti-bcl-2 PNA was stable for 168 h at 37 degrees C, unlike the conjugate containing the parent peptide sequence.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Genes, bcl-2. Lymphoma, B-Cell / genetics. Peptide Nucleic Acids / chemical synthesis. Peptides / chemical synthesis
  • [MeSH-minor] Cell Line, Tumor. Chromatography, High Pressure Liquid. Drug Delivery Systems. Fluorescent Dyes. Gene Expression Regulation, Neoplastic / drug effects. Heterocyclic Compounds, 1-Ring / chemistry. Humans. Indium Radioisotopes. Microscopy, Confocal. Molecular Structure. RNA, Messenger / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rhodamines / chemistry. Spectrometry, Fluorescence

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14624621.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86290
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fluorescent Dyes; 0 / Heterocyclic Compounds, 1-Ring; 0 / Indium Radioisotopes; 0 / Peptide Nucleic Acids; 0 / Peptides; 0 / RNA, Messenger; 0 / Rhodamines; 60239-18-1 / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
  •  go-up   go-down


10. Dagash H, Koh C, Cohen M, Sprigg A, Walker J: Inflammatory myofibroblastic tumor of the pancreas: a case report of 2 pediatric cases--steroids or surgery? J Pediatr Surg; 2009 Sep;44(9):1839-41
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the pancreas: a case report of 2 pediatric cases--steroids or surgery?
  • Inflammatory pseudotumors also termed inflammatory myofibroblastic tumors (IMTs) are rare, benign, solid lesions of unclear etiology more usually found in the lung and very rarely in the pancreas.
  • This represents the first reported case whereby steroid treatment has been successful in pancreatic IMT.
  • [MeSH-major] Glucocorticoids / therapeutic use. Granuloma, Plasma Cell / drug therapy. Granuloma, Plasma Cell / surgery. Pancreatic Diseases / drug therapy. Pancreatic Diseases / surgery. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Surg. 2010 May;45(5):1074-5; author reply 1075-6 [20438962.001]
  • (PMID = 19735837.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


11. Bahat G, Kalayoglu-Besisik S, Ozturk S, Kilicaslan I, Tunc M, Sargin D: Inflammatory pseudotumor following hematopoietic stem cell transplantation: a new case and review of the literature. Bone Marrow Transplant; 2007 Nov;40(10):915-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor following hematopoietic stem cell transplantation: a new case and review of the literature.
  • Inflammatory pseudotumor (IPT) is a rare tumor that occurs in various organs and tissues.
  • The clinical picture varies from the more frequent benign lesions to the rare malignant tumors with distant metastases.
  • IPT associated with hematopoietic stem cell transplantation (HSCT) is rarely reported.
  • A knowledge of this entity and insistence on a definitive biopsy of mass lesions in the post-HSCT period can avoid unnecessary treatment such as radical surgery, chemotherapy or radiotherapy.
  • [MeSH-major] Granuloma, Plasma Cell / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Urinary Bladder Diseases / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660842.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 22
  •  go-up   go-down


12. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-major] Carcinoma / pathology. Granuloma, Plasma Cell / pathology. Sarcoma / pathology. Urogenital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


13. Schneider G, Ahlhelm F, Altmeyer K, Aliani S, Remberger K, Schoenhofen H, Kramann B, Uder M: Rare pseudotumors of the urinary bladder in childhood. Eur Radiol; 2001;11(6):1024-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two cases of inflammatory pseudotumors of the urinary bladder, one case of a chronic granulomatous pseudotumor (CGT) and one case of a pseudosarcomatous myofibroblastic (fibromyxoid) tumor (PMT).
  • Awareness of these benign lesions may prevent patients from inappropriate therapies such as chemotherapy or radiation therapy.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Image Enhancement. Magnetic Resonance Imaging. Urinary Bladder Diseases / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Cell Division / physiology. Child, Preschool. Diagnosis, Differential. Humans. Male. Necrosis. Urinary Bladder / pathology. Urinary Bladder / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11419148.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Kardziev B, Hotzel B, Jachmann M: [The angiofollicular lymph node hyperplasia Castleman--casuistic and review of the literature]. Pneumologie; 2006 Apr;60(4):229-34
Genetic Alliance. consumer health - Angiofollicular Lymph Hyperplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Castleman Disease, also known as angiofollicular lymph node hyperplasia is a rare disorder that results in abnormal proliferation of B-lymphocytes and plasma cells in lymphoid organs.
  • On the basis of histologic criteria it has been divided into hyaline-vascular and plasma cell variant.
  • The hyaline-vascular type (90 % of cases), generally benign, occurs in younger patients with a localised mediastinal mass - surgical excision is curative.
  • The plasma cell variant (10 % of cases), localised or multicentric, is generally aggressive, and occurs in older patients with generalised lymphadenopathy, hepatosplenomegaly, systemic symptoms, anaemia, elevated inflammatory indices, and a polyclonal rise in immunoglobulins.
  • The prognosis is poor despite the Chemotherapy.
  • We present two cases of unicentric Castleman Tumor of hyaline-vascular type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16586203.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Kaji M, Kabir-Salmani M, Anzai N, Jin CJ, Akimoto Y, Horita A, Sakamoto A, Kanai Y, Sakurai H, Iwashita M: Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer; 2010 Apr;20(3):329-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
  • HYPOTHESIS: To investigate the expression and the functional properties of L-type amino acid transporter 1 (LAT1) in human epithelial ovarian cancer to provide a basis for potential new therapies to control the growth and the metastasis of ovarian cancer.
  • The expression of LAT1 in 53 cases of ovarian cancers was determined by Western blot and immunohistochemical staining, and results were compared with those of normal ovarian tissues (5 cases) and benign ovarian tumors (5 cases).
  • Furthermore, we examined the effect of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), the classic inhibitor of system L on the survival, the migration, and the uptake of l-leucine by human epithelial ovarian cancer cell line (OVCAR-3).
  • RESULTS: The LAT1 was significantly up-regulated in various human epithelial ovarian cancers that was localized predominantly on their plasma membrane and in the plasma membrane of the ovarian cancer cell line in conjunction with 4F2hc via disulfide bonds.
  • Then, LAT1 inhibition would be useful for anticancer therapy in suppressing tumor growth without affecting normal tissues.
  • [MeSH-minor] Amino Acids, Cyclic / pharmacology. Blotting, Western. Cell Adhesion / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Female. Fluorescent Antibody Technique. Humans. Immunoenzyme Techniques. Leucine / metabolism. Ovary / drug effects. Ovary / metabolism. Ovary / pathology. Peptide Fragments / immunology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375792.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Cyclic; 0 / Large Neutral Amino Acid-Transporter 1; 0 / Peptide Fragments; 20448-79-7 / 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid; GMW67QNF9C / Leucine
  •  go-up   go-down


16. Wen SL, Zhou X, Hu HH, Peng ZZ: [Clinical characteristics of 8 cases of primary tracheal tumors]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep;32(9):660-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the clinical characteristics of primary tracheal tumors and therefore to improve the diagnosis and treatment.
  • METHODS: A retrospective analysis of the clinical data of 8 patients with primary tracheal tumors admitted to our department during the period of May 1994 to May 2006 was performed, with detailed description of the clinical manifestations, chest radiography, fiberoptic bronchoscopy, lung function measurements, treatment and prognosis for 4 cases.
  • Examination by fiberoptic bronchoscopy confirmed the diagnosis of tracheal tumor in all the cases.
  • One case with benign neurinoma and 2 cases with adenoid cystic carcinomas had a long-term postoperative remission.
  • Two cases of squamous cell carcinoma with severe tracheal stenosis got rapid symptom remission after intervention of tracheal stent by fiberoptic bronchoscopy and argon plasma coagulation.
  • One patient with adenoid cystic carcinoma refused any treatment.
  • One patient with squamous cell carcinoma lost follow-up after surgery.
  • One patient with adenocarcinoma died of progressive deterioration after 2 month chemotherapy.
  • Benign tracheal tumors can be resected, and for some low-grade malignant tumors surgical resection and postoperative radiotherapy can improve long term survival.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / therapy. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079278.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, Tarabuzzi R, Poggio M, Torta M, Fontana D, Angeli A: Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol; 2001;12 Suppl 2:S153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine (NE) differentiation of prostate adenocarcinoma has received increasing attention in recent years as a result of possible implications for prognosis and therapy.
  • The presence of NE tumor subpopulation can be gauged non invasively by measuring circulating levels of secretory products, primarily chromogranin A (CgA).
  • RESULTS: Circulating CgA levels were found to be higher in prostate cancer patients than in patients with benign or pre-malignant prostatic diseases.
  • CgA values were not substantially affected by either endocrine therapy or chemotherapy.
  • The administration of a somatostatin analog in hormone refractory cases was able to reduce plasma CgA values consistently.
  • Serial evaluation of circulating CgA could provide information on changes in the NE phenotype expression as a consequence of tumor progression and/or treatment administration.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762344.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; 0 / CHGA protein, human; 0 / Chromogranin A; 0 / Chromogranins; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 42
  •  go-up   go-down


18. Ilias I, Pacak K: Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res; 2005 Dec;37(12):717-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are chromaffin-cell tumors; 80-85 % arise from the adrenal medulla and 15-20 % arise from extra-adrenal chromaffin tissues (paragangliomas).
  • The diagnosis of pheochromocytoma should first be established biochemically by measuring plasma free metanephrines (the measurement of urinary fractionated metanephrines is the second choice).
  • Anatomical (radiological) imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is necessary for both pheochromocytomas and neuroblastomas.
  • Other newer specific modalities that have been used for evaluating pheochromocytomas include positron emission tomography (PET) with [18F]-F-fluorodopamine (F-DA) and [18F]-F-dihydroxyphenylalanine (DOPA).
  • Primary treatment for both types of tumor is surgical; chemotherapy is used for inoperable disease.
  • After successful surgery, survival of patients with benign, sporadic pheochromocytomas is believed to be equal to that of the general population.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Adrenal Medulla / physiopathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Humans. Multiple Endocrine Neoplasia Type 2a / diagnosis. Multiple Endocrine Neoplasia Type 2a / therapy. Neuroblastoma / diagnosis. Neuroblastoma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372223.001).
  • [ISSN] 0018-5043
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


19. Su W, Ko A, O'Connell T, Applebaum H: Treatment of pseudotumors with nonsteroidal antiinflammatory drugs. J Pediatr Surg; 2000 Nov;35(11):1635-7
Hazardous Substances Data Bank. NAPROXEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pseudotumors with nonsteroidal antiinflammatory drugs.
  • Also, there is a lack of other reliable therapy for this clinically aggressive yet histologically benign disease characterized by an overreactive inflammatory response.
  • The authors treated 2 cases of abdominal IPT with nonsteroidal antiinflammatory drug (NSAID) with successful results.
  • After a diagnosis of IPT on tumor biopsy, an NSAID trial can confirm the diagnosis and treat the disease by causing tumor shrinkage and eventual resolution.
  • Excision remains indicated in easily resectable tumors and in nonresponders to NSAID therapy.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Colonic Diseases / drug therapy. Granuloma, Plasma Cell / drug therapy. Hydronephrosis / drug therapy. Ibuprofen / administration & dosage. Naproxen / administration & dosage
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083441.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 57Y76R9ATQ / Naproxen; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


20. Ueda M, Yukihide Y, Ogawa K, Haga H, Ogura Y, Ito T, Tanaka K: A case of inflammatory pseudotumor of the liver hilum successfully treated with aggressive hepatectomy. J Pediatr Surg; 2003 Nov;38(11):E9-11
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory pseudotumor (IPT) of the liver is a rare, benign tumor.
  • When the tumor involves the hepatic hilum, however, the clinical course of the patient becomes problematic because of obstructive jaundice and portal hypertension.
  • Complete removal of the tumor sometimes is difficult when the hepatic hilum is extensively involved, and liver transplantation becomes necessary for such an unresectable tumor.
  • The liver has continued to function well for 11 months after the tumor resection.
  • [MeSH-major] Granuloma, Plasma Cell / surgery. Hepatectomy. Liver Diseases / surgery
  • [MeSH-minor] Bile Ducts / surgery. Catheterization. Child. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / surgery. Constriction, Pathologic / etiology. Constriction, Pathologic / surgery. Hepatic Artery / surgery. Humans. Male. Portal Vein / surgery. Postoperative Complications. Thrombolytic Therapy. Thrombosis / drug therapy. Venous Thrombosis / etiology. Venous Thrombosis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614735.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Colakoglu O, Unsal B, Haciyanli M, Tunakan M, Buyrac Z, Yorukoglu G, Yazicioglu N, Genc H: A succesfully managed inflammatory pseudotumour of liver without surgery: report of a case. Acta Gastroenterol Belg; 2005 Jul-Sep;68(3):382-4
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has the appearance of a malignant tumor but has a benign histology and clinical course.
  • After the initiation of the antibiotic and nonsteroidal anti-inflammatory drugs (NSAID), the size of hepatic pseudotumor decreased (20 x 20 mm) and then completely disappeared.
  • After the diagnosis, IPT gave an excellent response to short course of antibiotic and NSAID therapy.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Granuloma, Plasma Cell / drug therapy. Liver Diseases / drug therapy
  • [MeSH-minor] Disease Progression. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268428.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


22. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, Korol DL, Wallig MA, Helferich WG: Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis; 2004 Feb;25(2):211-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the estrogenic properties of soy-derived isoflavones, many postmenopausal women are using these compounds as a natural alternative to hormone replacement therapy (HRT).
  • Chemical induction of mammary tumors in female rats has been used to determine that exposure of the mammary gland to soy isoflavones prior to tumor induction is protective against tumor formation.
  • Animals were ovariectomized (OVX) after mammary tumor development and were then placed into one of three treatment groups: positive-control (OVX+ estradiol implant), genistein (OVX+ 750 p.p.m. genistein) and negative-control (OVX alone).
  • Tumors were distinguished as malignant or benign by histopathological examination and were further characterized as either estrogen-dependent or estrogen-independent using immunohistochemistry to identify the presence of both estrogen receptor (ER) alpha and the progesterone receptor (PR).
  • Genistein treatment also resulted in a higher percentage of proliferative cells in tumors and increased uterine weights when compared with negative-control animals.
  • Plasma genistein concentrations in animals fed the isoflavone-containing diet were at physiological levels relevant to human exposure.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animal Feed. Animals. Anticarcinogenic Agents / administration & dosage. Cell Division / drug effects. Diet. Drug Synergism. Estrogens / metabolism. Female. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Uterus / drug effects. Uterus / growth & development

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14578162.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA77355; United States / NIEHS NIH HHS / ES / T32 ES 07320
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anticarcinogenic Agents; 0 / Estrogens; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 684-93-5 / Methylnitrosourea; DH2M523P0H / Genistein
  •  go-up   go-down






Advertisement